The livestock cycle is not a whim of the market, but is built with the convergence of numerous variables with a life of their own but which, ultimately, depends on the expectations that the sector, the trend of beef consumption and that of other competitive and the signals that the price gives to producers so that they retain or liquidate their main capital: the rodeo they manage.
The check. The Argentine beef stock at the beginning of 2026 is estimated at 50.9 million heads, with an interannual drop of more than 700,000 animals, a minimum level of the last decade. This reduction in supply, together with strong export demand, anticipates high prices and lower availability for domestic consumption. According to estimates and projections by the Association of Argentine Exporting Producers, in all scenarios for Argentine livestock farming in 2026, a reduction in the supply of beef is expected as a result of a drop in bovine slaughter, according to analysis carried out by the Livestock area of CREA in the Livestock Outlook.
“The use of animal health products is directly linked to the growth in demand for animal protein worldwide.”holds Juan Roogeneral manager of the laboratory CDV, an Argentine company that has a 30% share of the global market, on the rise. These perspectives are closely marked by the greater global demand for food, the need for productive efficiency and the growing health requirements for exports. “There are opportunities to export meat and good market prices, but we lack production and the cycles are long”he adds. And in order to rebuild the national stock, in addition to retaining bellies, it is key to increase the productivity of the current cow herd: out of every 100 cows, only 65 manage to produce a calf.
In that sense, a good health prevention and management plan is necessary for the herd to grow and be able to supply Argentina’s demand for meat. “With a clearer long-term outlook, we have no doubt that the producer, together with his veterinarian and the technical teams of laboratories like ours, can achieve it,” he says.
The process. CDV is a local laboratory specialized in the development and production of vaccines and reagents for animal health, with a strategic approach focused on prevention as the axis of productive sustainability. Its production model is distinguished by a complete integration of the value chain: research, development, diagnosis, manufacturing, marketing and after-sales service, all under international quality and biosafety standards. CDV has more than 60 products aimed at prevention in multiple species, cattle, sheep, pigs, poultry, aquaculture and companion animals, which reinforces its positioning as an integral player in animal health.
The laboratory is positioned as one of the main actors in animal health in Argentina with a business model that is supported by a network of veterinarians and specialized distributors, complemented by a technical service that works together with producers and professionals in the design of preventive health plans adapted to each production system.
The company currently has 270 direct collaborators and is in the process of expanding its team. Its production complex is carried out in the operation of three plants in the Pilar Industrial Park, with different levels of specialization and biosafety, where vaccines and key reagents are produced, such as Brucella, Rabies, PPD, reproductive and respiratory complexes and foot-and-mouth vaccine, consolidating one of the most complete portfolios in the region. At the same time, it has one of the most important diagnostic laboratories that allows real-time monitoring of the health evolution of the herds.
The start-up of Plant 3, which required an investment of US$100 million between the end of 2023 and 2025, marks a turning point in its growth strategy, enabling new opportunities for diversification and expansion. In this sense, the company is in the final stage of developing new lines aimed at pigs and pets, while deepening the incorporation of innovative technologies in vaccines and expanding its presence in international markets, such as the recent signing of a vaccine supply agreement for all of Europe starting in 2027. This evolution responds to a long-term vision aimed at anticipating health and production demands at a global level.
R&D. The animal health market is highly competitive and is made up of multinational, regional companies and local players with strong technical development. In this context, CDV builds its differential from a combination of strategic factors: proximity to veterinarians and producersdeep knowledge of local health problems, capacity for innovation and a sustained investment policy.
Innovation constitutes a structural axis in CDV’s development model and is the result of a trajectory of more than 40 years in animal health.. The company maintains a constant investment policy that, in the last decade, exceeded US$150 million allocated to productive infrastructure, cutting-edge technology and development of scientific capabilities.
From its origins as a family veterinary diagnostic center in the Saavedra neighborhood, in the City of Buenos Aires, CDV evolved into an industrial complex of international scale, with three production plants in Pilar, a qualified team and a growing global insertion, as part of a multinational group of German capital. TOIt does consolidate a growing global presence, currently exporting to more than 30 countries and in the process of registering in 25 more countries as part of its strategy. of growth and expansion, certifying high quality standards worldwide. A commitment to applied science and innovation.
You may also be interested
by Marcelo Alfano
